Seeking Alpha

Wall Street Tea...'s  Instablog

Wall Street Teacher
Send Message
Wall Street Teacher (a pseudonym) worked on Wall Street for several years in the fixed income area and now teaches and writes on financial topics (primarily regulation and markets). Current interests include the psychology of financial markets, the origins of chemistry/physics, synthetic... More
  • Ziopharm- MSK Trial Initiated 0 comments
    Apr 8, 2010 9:01 AM | about stocks: ZIOP






    Out this AM. ZIO-301 is ZIOP's earliest stage drug candidate. MSK/Norton-not bad company.

    ZIOPHARM Commences Oral Indibulin Phase I/II Trial in Breast Cancer -- at Memorial Sloan-Kettering Cancer Center --

    ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

    The Phase I trial is expected to enroll approximately 20 patients and will determine the maximum tolerated dose of oral indibulin implementing the “mathematically modeled” dose administration schedule - 5 days on and 9 days off - that capitalizes on the convenience of oral administration, but also maximizes drug activity, limiting potential toxicity and resistance.

    Indibulin is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. It is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy, and minimal overall toxicity. In multiple Phase I trials, oral indibulin has been administered both as a single agent and in combination with favorable activity, and has a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. The trial will be continued into Phase II once dose has been established in Phase I.

    Clifford A. Hudis, M.D., Chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, noted, “The development of an additional new therapy for breast cancer that is effective but with fewer of the more significant side effects associated with many commonly used therapies would be an important step in the treatment of this disease. We look forward to testing this novel agent and dosing schedule in patients.”

    The study will implement a mathematically modeled drug administration schedule that was developed in preclinical studies by Larry Norton, M.D. as a consultant to ZIOPHARM Oncology, Inc. The model capitalizes on the convenience and scheduling flexibility of oral administration to maximize anticancer activity, minimize potential toxicity and resistance, and exploit the drug’s mechanisms of action on both cancer cell division and cell movement. Findings from the preclinical studies were presented at the 2009 American Society of Clinical Oncology annual meeting.

    Memorial Sloan-Kettering’s Breast Cancer Medicine team, under the direction of Dr. Hudis, has successfully translated preclinical work into meaningful clinical treatment in past studies, and will lead this Phase I/II trial.

    For more details about this trial, please see www.clinicaltrials.gov.

    http://www.thestreet.com/story/10720926/1/ziopharm-commences-oral-indibulin-phase-iii-trial-in-breast-cancer--at-memorial-sloan-kettering-cancer-center--.html?cm_ven=GOOGLEFI
     


    Disclosure: Very Long ZIOP
    Themes: Biotech Cancer Stocks: ZIOP
Back To Wall Street Teacher's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • CorMedix: Making Progress In Both EU Commercial And U.S. Regulatory Fronts $CRMD http://seekingalpha.com/a/19v93
    Apr 14, 2014
  • Cormedix: An Interesting Play In The Catheter Care Space $CRMD http://seekingalpha.com/a/1582p
    Dec 31, 2013
  • I'm betting Europe works out. That's bad for the $ but good for gold. I guess the Germans rule the continent without having to fire a shot!
    Jun 4, 2012
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.